Multiple Sclerosis Drugs - Worldwide

  • Worldwide
  • The Multiple Sclerosis Drugs market is forecasted to achieve a remarkable revenue of US$22.61bn by the year 2024.
  • This projection indicates a steady annual growth rate of 0.98% between 2024 and 2028, leading to a market volume of US$23.51bn by 2028.
  • In terms of global comparison, it is anticipated that United States will generate the highest revenue, with an estimated US$12,360.00m in 2024.
  • The country's contribution to the market of Multiple Sclerosis Drugs market worldwide is significant.
  • Worldwide, there is a growing demand for innovative and personalized multiple sclerosis drugs, as countries strive to improve patient outcomes and quality of life.

Key regions: South Korea, Brazil, Australia, China, Japan

Region comparison

Analyst Opinion

The market for Multiple Sclerosis Drugs has been steadily growing worldwide, driven by increasing awareness and diagnosis of the disease.

Customer preferences:
Patients suffering from Multiple Sclerosis prefer drugs that can effectively manage their symptoms and improve their quality of life. They also seek medications that have minimal side effects and are affordable. Additionally, there is a growing preference for oral medications over injectables.

Trends in the market:
In the United States, the Multiple Sclerosis Drugs market is dominated by oral medications, with a shift away from injectables. This trend is driven by the convenience and ease of use of oral medications, which are also associated with fewer adverse events. In Europe, however, injectables remain the primary treatment option for Multiple Sclerosis, with a slower uptake of oral medications. This is due to differences in healthcare policies and reimbursement systems across countries. In emerging markets such as China and India, there has been a significant increase in the diagnosis of Multiple Sclerosis, leading to a surge in demand for medications. This has led to the entry of new players in the market, as well as the introduction of biosimilars and generics.

Local special circumstances:
In Japan, there is a higher prevalence of a specific type of Multiple Sclerosis known as neuromyelitis optica spectrum disorder (NMOSD). This has led to the development of drugs specifically for this condition, such as eculizumab and satralizumab, which have shown promising results. In Latin America, access to treatment and healthcare infrastructure remain major challenges, leading to a significant treatment gap for Multiple Sclerosis patients. This has led to the introduction of innovative pricing models and patient assistance programs by pharmaceutical companies to improve access to medications.

Underlying macroeconomic factors:
The global rise in healthcare expenditure, increasing prevalence of Multiple Sclerosis, and advancements in drug development are key macroeconomic factors driving the growth of the Multiple Sclerosis Drugs market. Additionally, the increasing focus on personalized medicine and the development of drugs targeting specific subtypes of Multiple Sclerosis is expected to further drive market growth in the coming years.


Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.


In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.


  • Revenue
  • Analyst Opinion
  • Key Players
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait


Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)